tbuckley/cabot-search huggingface dataset:
Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment
Authors: Zafar Iqbal, Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad Sultan, Ammara H Tahir, Muhammad Absar, Muhammad Azhar Chishti, Muhammad Faiyaz -ul-Haque, Ahmed Mukhtar Khalid, Muhammad Farooq Sabar, Mahmood Rasool, Agha Shabbir Ali, Amer Mahmood, Muhammad Akram, Tariq Saeed, Saleem Arsalan, Danish Mohsin, Ijaz Husssain Shah, Muhammad Khalid, Muhammad Asif, Mudassar Iqbal, Tanveer Akhtar
Journal: Blood (2012)
Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT+S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)
Authors: G. Crehange, F. Bonnetain, S. Seng, T. N'guyen, X. Mirabel, C. Marchal, P. Verrelle, B. Roullet, P. Maingnon, L. Bedenne
Journal: Journal of Clinical Oncology (2007)

4531 Background: The FFCD 9102 trial demonstrated that CRT is an alternative to CRT+S for responding patients. We investigated the type of PP in the follow-up (FU) period, according to the RT scheme: protracted (P-RT) vs. split course (SC-RT). Methods: Resectable T3 N0–1 M0 thoracic esophageal carcinoma were included. First sequence : 2 cycles of cisplatin and 5-FU (day (d)1 - d22) combined with RT. Two schemes of RT were allowed: P-RT (46 Gy / 4.5 weeks (w), 2 Gy / f) or SC-RT (2 one-week courses of 15 Gy, 3 Gy / f). For CRT, the same chemotherapy was given on d43, d64 and d92 combined with 20 Gy / 2w (P-RT) or 15 Gy / 1w (SC-RT). Responding patients after the first sequence were randomized between CRT and CRT+S. The impact of SC-RT vs. P-RT on PP in the FU period was explored using a Mann-Whitney test. Results: From February 1993 to December 2000, 451 pts were registered and 446 were eligible. P-RT: 161 pts, SC-RT: 285 pts. After a median FU of 47.4 months, 2-year overall survival and local relapse-free survival were for P-RT vs. SC-RT: 37.1% vs. 30.5% (p = 0.25) and 76.7% vs. 56.8% (p = 0.002), respectively. P-RT vs. SC-RT: mean length of hospital stay: 48 d vs. 60.5 d (p= 0.0003). Mean number of dilatation sessions: 0.56 vs. 0.66 (p= 0.43). Mean number of stents: 0.21 vs. 0.34 (p= 0.03). Mean number of any PP: 1.01 vs. 1.50 (p= 0.001). Mean dysphagia grade: 2.99 vs. 3.12 (p= 0.21). In the CRT+S-group, P-RT vs. SC-RT: mean length of hospital stay 55.0d vs. 68.7d (p =0.051). Mean number of dilatation sessions: 0.74 vs. 0.74 (p= 0.77). Mean number of stents: 0.09 vs. 0.18 (p= 0.44). Mean number of PP: 1.00 vs. 1.37 (p= 0.054). In the CRT-group, P-RT vs. SC-RT, mean length of hospital stay: 42.6d vs 54.0d (p= 0.053). Mean number of dilatation sessions : 0.38 vs. 0.67 (p= 0.12). Mean number of stents: 0.31 vs. 0.50 (p= 0.03). Mean number of PP: 0.83 vs. 1.86 (p= 0.0005). Conclusions: Stents, rate of PP and length of hospital stay were significantly increased with SC-RT. Dysphagia score was similar between SC-RT and P-RT at last FU. No significant financial relationships to disclose.
Single-cell imaging of normal and malignant cell engraftment into optically clear <i>prkdc</i>-null SCID zebrafish
Authors: John C. Moore, Qin Tang, Nora Torres Yordán, Finola E. Moore, Elaine G. Garcia, Riadh Lobbardi, Ashwin Ramakrishnan, Dieuwke L. Marvin, Anthony Anselmo, Ruslan I. Sadreyev, David M. Langenau
Journal: The Journal of Experimental Medicine (2016)

Cell transplantation into immunodeficient mice has revolutionized our understanding of regeneration, stem cell self-renewal, and cancer; yet models for direct imaging of engrafted cells has been limited. Here, we characterize zebrafish with mutations in recombination activating gene 2 (rag2), DNA-dependent protein kinase (prkdc), and janus kinase 3 (jak3). Histology, RNA sequencing, and single-cell transcriptional profiling of blood showed that rag2 hypomorphic mutant zebrafish lack T cells, whereas prkdc deficiency results in loss of mature T and B cells and jak3 in T and putative Natural Killer cells. Although all mutant lines engraft fluorescently labeled normal and malignant cells, only the prkdc mutant fish reproduced as homozygotes and also survived injury after cell transplantation. Engraftment into optically clear casper, prkdc-mutant zebrafish facilitated dynamic live cell imaging of muscle regeneration, repopulation of muscle stem cells within their endogenous niche, and muscle fiber fusion at single-cell resolution. Serial imaging approaches also uncovered stochasticity in fluorescently labeled leukemia regrowth after competitive cell transplantation into prkdc mutant fish, providing refined models to assess clonal dominance and progression in the zebrafish. Our experiments provide an optimized and facile transplantation model, the casper, prkdc mutant zebrafish, for efficient engraftment and direct visualization of fluorescently labeled normal and malignant cells at single-cell resolution.
Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors.
Authors: J. Xu, Y. Wang, C. Y. Ye, C. Huang, X. H. Zhang, Y. Sai, L. Shen, H. MU
Journal: Journal of Clinical Oncology (2011)

e13558 Background: Sulfatinib is a highly selective oral small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 and fibroblast growth factor receptor (FGFR) 1, developed by Hutchison MediPharma. It demonstrated potent in vivo inhibitory effects on a variety of human tumor xenografts. The current study was designed to evaluate safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of sulfatinib. Methods: Eligible patients with histopathologically confirmed solid tumors that had previously failed standard therapies were to be enrolled in cohorts of escalating sulfatinib doses given orally once a day of 28-day cycles until disease progression or unacceptable toxicity. A standard 3+3 design was used for dose escalation, followed by an expanded cohort at maximum tolerated dose (MTD). Results: As of 01/2011, 18 patients have been enrolled in 5 dose cohorts of 50, 75, 110, 150 and 200 mg sulfatinib. Patients had a median age of 50 (36-70) yrs, 56% being male, ECOG performance status 0-2, and tumor types including colorectal, liver, gastric, esophageal, cervical, and neuroendocrine cancer. The most common adverse events (AEs) were fatigue, vomiting, nausea, diarrhea, and elevated AST, all in grade 1/2. Three patients had grade 3 AEs including one dose limiting toxicity of grade 3 coagulation disorder in a patient with cervical cancer in the 50 mg cohort. Two patients experienced SAEs (1 grade 3 epilepsy and an intestinal obstruction which was the only grade 4 AE to date), both in the 50 mg cohort. MTD has not been reached and the dose escalation is ongoing at 200 mg. Among 14 evaluable patients, two had stable disease for 8 weeks or longer. Preliminary PK analyses showed that sulfatinib was rapidly absorbed at all studied doses with Tmax 1.3~2.8h and half-life of 15.3~17.3h. Cmax and AUC displayed dose-proportional increases and no obvious accumulation occurred at day 28. Conclusions: Sulfatinib was well tolerated at doses up to 150 mg. Preliminary PK data suggests dose-proportional increases in exposure over the evaluated doses. Dose-escalation is currently ongoing at 200 mg. Updated data will be presented.
Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC)
Authors: R. Lin, Q. Chen, N. Fan, Y. Ye, Z. Guo, X. Wang, J. Liu, L. Chen
Journal: Journal of Clinical Oncology (2009)

e15642 Background: Primary results of POF as 1st and 2nd line treatment for AGC have been presented at ASCO 2007 and 2008. We report here data on the feasibility and the toxicity of POF versus IF(Dank, et al, ASCO 2005) in 1st line treatment of AGC. Methods: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment. Treatment was continued until disease progressed, unacceptable toxicity, or patient choice. Results: 25 patients were entered in this study between March 2007 and July 2007: 13 in the POF group and 12 in the IF group. The median patient age was 55 years (range, 36 to 67 years), 18 were males and 7 were females. No complete response was observed. The response rate was 62.5% (POF) and 33.3% (IF) respectively. At a median follow-up of 285 days, 7(POF) versus 6(IF) patients were still alive. Hematological toxicity was the most frequent toxicity in both groups. Grade 3 to 4 neutropenia were 38.5% (POF) versus 8.3% (IF). Diarrhea was found 0% and 8.3% in POF and IF group respectively. No grade 3 peripheral neurotoxicity was observed. Conclusions: Compared with IF regiment, POF could also be used as first-line treatment for AGC with acceptable safety profile, good efficacy, and more encouraging results. No significant financial relationships to disclose.
Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study
Authors: J. Graff, M. Mori, H. Li, M. Garzotto, D. Penson, A. Potosky, T. M. Beer
Journal: Journal of Clinical Oncology (2006)

4610 Background: Use of PADT as sole therapy for clinically localized PC is rapidly increasing, despite little evidence to support this approach. We examined predictors of overall survival (OS) and cancer-specific survival (CSS) using the data available from the Prostate Cancer Outcome Study (PCOS). Methods: PCOS recruited 5,672 patients between 1994 and 1995, within 6 months of PC diagnosis. Vital status was last updated in 12/02. 276 patients had clinically localized PC and received PADT. We examined the relationship between baseline demographic, socio-economic, and tumor factors and OS and CSS using Kaplan-Meier and Cox regression methods implemented in the SUDAAN software. Results: Of 276 patients, 148 patients have died, 35 from PC. The median age at diagnosis was 75 (50–88). The average follow-up of censored subjects was 7.6 yrs (1.1–8.1). 5-year OS was 66% (95% CI: 69–72), while the 5-year CSS was 91% (95% CI: 86–94). In the multivariate analysis (see Table), age, serum PSA at diagnosis, and Gleason score were the only independent predictors of OS. Abnormal DRE was marginally significant. The Gleason score (≥7) was the only independent predictor of CSS (HR 4.0, p = 0.04); PSA ≥ 20 (HR 2.38, p = 0.09) approached significance. This analysis was limited by a smaller number of deaths due to prostate cancer (n = 35). Conclusions: In an analysis that included a broad range of demographic and socio-economic factors, overall survival of patients with clinically localized prostate cancer treated with PADT was predicted by age and measures of tumor biology (Gleason score) and tumor mass (serum PSA). Thus, cancer remains an important contributor to overall mortality in these patients, particularly those with high Gleason score and high serum PSA. These data can be used to inform patients regarding their individual 5-year survival if they choose PADT for the treatment of their clinically localized prostate cancer. [Table: see text] No significant financial relationships to disclose.
Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.
Authors: Olaf Penack, Lars Fischer, Andrea Stroux, Chiara Gentilini, Axel Nogai, Arne Muessig, Susanne Ganepola, Eckhard Thiel, Lutz Uharek
Journal: Blood (2006)
Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
Authors: Saad Usmani, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie
Journal: Blood (2011)
A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial
Authors: Gordon Cook, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, Christopher Parrish, Kwee L Yong, Jim Cavet, Hannah Hunter, Jennifer Bird, Guy Pratt, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, Julia Brown, Curly Morris
Journal: Blood (2015)
Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology
Authors: Stephen L. Kopecky, Douglas C. Bauer, Martha Gulati, Jeri W. Nieves, Andrea J. Singer, Peter P. Toth, James A. Underberg, Taylor C. Wallace, Connie M. Weaver
Journal: Annals of Internal Medicine (2016)

Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known.The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided by an independent evidence review team at Tufts University.The National Osteoporosis Foundation and American Society for Preventive Cardiology adopt the position that there is moderate-quality evidence (B level) that calcium with or without vitamin D intake from food or supplements has no relationship (beneficial or harmful) to the risk for cardiovascular and cerebrovascular disease, mortality, or all-cause mortality in generally healthy adults at this time. In light of the evidence available to date, calcium intake from food and supplements that does not exceed the tolerable upper level of intake (defined by the National Academy of Medicine as 2000 to 2500 mg/d) should be considered safe from a cardiovascular standpoint.
Hematuria as a Marker of Occult Urinary Tract Cancer
Authors: Matthew Nielsen, Amir Qaseem
Journal: Annals of Internal Medicine (2016)

Letters18 October 2016Hematuria as a Marker of Occult Urinary Tract CancerMatthew Nielsen, MD, MS and Amir Qaseem, MD, PhDMatthew Nielsen, MD, MSFrom University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and American College of Physicians, Philadelphia, Pennsylvania.Search for more papers by this author and Amir Qaseem, MD, PhDFrom University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and American College of Physicians, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0328 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Brown's first point addressing cases where the clinical presentation suggests glomerular sources is well-taken. As we discussed, current guidelines differ in their recommendations for evaluation of patients with hematuria who have findings suggestive of potential nephrologic disorders, such as hypertension, renal insufficiency, cellular casts, proteinuria, or dysmorphic erythrocytes. The American Urological Association and British Association of Urological Surgeons recommend concurrent nephrologic and urologic evaluation in this context, whereas the Canadian and Dutch guidelines suggest referral to a nephrologist as an alternative starting point. We also noted in the Limitations of the Evidence section that such presentations logically ... Author, Article, and Disclosure InformationAffiliations: From University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and American College of Physicians, Philadelphia, Pennsylvania.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-1496. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians Matthew Nielsen , Amir Qaseem , and Hematuria as a Marker of Occult Urinary Tract Cancer Robert S. Brown Metrics Cited byCancer Prevalence and Risk Stratification in Adults Presenting With Hematuria: A Population-Based Cohort StudyGuideline of guidelines: asymptomatic microscopic haematuria 18 October 2016Volume 165, Issue 8Page: 602KeywordsBladder cancerCystoscopyDisclosureHypertensionMedical risk factorsNephrologyProteinuriaSurgeonsUrology ePublished: 18 October 2016 Issue Published: 18 October 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Combination of ATRA with a COX2 Inhibitor Induces Synergistic Effects On RARalpha2-Expressing Multiple Myeloma (MM) Cells.
Authors: Siqing Wang, Lei Shi, Hongwei Xu, Chunjiao Xu, Maurizio Zangari, Guido J. Tricot, Fenghuang Zhan
Journal: Blood (2009)
Survivorship patterns of a large nationwide cohort of elderly veterans with colorectal cancer
Authors: K. S. Virgo, M. P. Valentine, L. Dauz, L. H. Marietta, B. Adams, S. Devarajan, W. E. Longo, F. E. Johnson
Journal: Journal of Clinical Oncology (2006)

13525 Background: Administrative databases are not designed to permit cancer researchers to readily follow patients from the period pre-diagnosis through initial curative intent treatment, adjuvant therapy, post-treatment follow-up, to either death or loss to follow-up. One major hurdle to cancer research using such databases has been the lack of data such as stage at diagnosis, and histopathologic type and grade. A second major hurdle is that many patients use more than one system of care, in this instance, Department of Veterans Affairs (VA) and Medicare-reimbursed care. These dual users would be inaccurately represented in the analysis if only one source of data were analyzed. Methods: A retrospective analysis of 13 years of nationwide Medicare and VA inpatient and institutional outpatient data beginning with the three years pre-diagnosis (1986–1990) through a minimum of five years post-diagnosis (1994–1998) was conducted. Death data were available through June 2005. Data were also extracted from tumor registry files, Computerized Patient Record System Files, and paper medical records at each VA. The population studied included all VA patients diagnosed with colorectal cancer and surgically treated for cure during the five-year period 1989–1993, who were Medicare-eligible at diagnosis, and survived the index admission. Results: Of the 6612 patients treated with curative intent during the five-year period, 4924 (74%) could be staged. Of these, 4551 (92%) were deemed eligible for the study. Of the eligible patients, 77% were diagnosed with colon cancer and 23 percent with rectal cancer. The majority (89%) had adenocarcinoma. The histopathologic grade was moderately differentiated for 54% and well differentiated for 19%. As of June 2005, 77% had died. Including all stages (0- IV), the average survival in months after treatment was 86 (median=61). Survivorship differed significantly by stage at diagnosis (p &lt; .001). Conclusions: This rich database provides a wealth of data for subgroup analyses of survivorship, recurrence patterns, and health services utilization patterns within and across systems of care. Identifying predictors of survivorship within subgroups of this population is currently under way [Table: see text]
High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.
Authors: L. Mannone, C. Gardin, M.C. Quarre, J.F. Bernard, S. Giraudier, E. Rosenthal, D. Vassilief, F. Hamza, S. Park, J.J. Kiladjian, S. Vaultier, Mo Beyne-Rouzy, S. Cheze, L. Voilliat, P. Agape, F. Dreyfus, P. Fenaux
Journal: Blood (2004)
Eliglustat Tartrate, a Novel Investigational Oral Substrate Reduction Therapy for Gaucher Disease Type 1: Updated Phase 2 Results.
Authors: Elena Lukina, Judith Peterschmitt, Nora Watman, Marta Dragosky, Marcelo Iastrebner, Gregory Pastores, Elsa Avila Arreguin, Hanna Rosenbaum, Mici Phillips, Mathilde Kaper, Arshadul Haque, Ana Cristina Puga
Journal: Blood (2010)
Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis
Authors: Phu V. Troung, Marc Saltzman, Alberto Bessudo, William Jawien, Roger M. Lyons, Dmitriy Berenzon, Raul Mena, Nasiema Wingate-Pearse, Olivier Barriere, Hali E. Beeson, Paul F. Glidden, Gavin S. Choy, Srdan Verstovsek
Journal: Blood (2015)
The Role of Signal-Transducing Adaptor Protein-2 in Early T Lymphopoiesis in Thymus
Authors: Michiko Ichii, Natsuko Fujita, Daisuke Okuzaki, Tetsuo Maeda, Yuichi Sekine, Shigeyuki Kon, Ryuta Muromoto, Kenji Oritani, Tadashi Matsuda, Yuzuru Kanakura
Journal: Blood (2014)
GW26-e1537 Ticagrelor overcomes high on-clopidogrel treatment platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial
Authors: Pan Li, Yawei Yang, Tao Chen, Yu Liu, Junmei Liu, Xianxian Zhao, Yongwen Qin, Liping MA.
Journal: Journal of the American College of Cardiology (2015)
Percoll Gradient Separation of Cord Blood Mononuclear Cells Reveals the Presence of a Novel Population of CXCR4+ Oct-4+ Small Embryonic-Like Stem Cells.
Authors: Magda Kucia, Krzysztof Oldak, Mariusz Z. Ratajczak, Janina Ratajczak, Zygmunt Pojda
Journal: Blood (2005)
Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation
Authors: Jennifer M. Beswick, Elizabeth Shin, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Theodore Marras, Dennis Dong Hwan Kim
Journal: Blood (2015)
Refining the Diagnosis of Type 2 Myocardial Infarction
Authors: Yader Sandoval, Allan S. Jaffe
Journal: JAMA Cardiology (2016)

To the Editor Debate exists regarding how to distinguish type 2 from type 1 myocardial infarction (MI) and cardiac injury.1-3 Nagele2 now questions whether including supply-demand imbalance as the cause of ischemia expands the use of the term too broadly.